Provectus Pharmaceuticals Inks $1 Million

Provectus Pharmaceuticals, a biotech company developing oncology and dermatology drugs, has inked a $1 million investment from Chicago-based Lincoln Park Capital Fund. As part of the deal, Lincoln Park committed to invest up to $30 million more in equity capital. Provectus is traded on the over-the-counter Bulletin Board.

North AmericaUSBriefs